28 April 2022 – With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), BenevolentAI (formerly known as Odyssey Acquisition S.A.) announces that notifications of transactions by persons discharging managerial responsibilities are available on the Luxembourg Stock Exchange’s electronic database OAM on www.bourse.lu and on BenevolentAI’s web site www.benevolent.com.
ENDS
ABOUT BENEVOLENTAI
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable insititutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. .
Contacts for BenevolentAI:
Media:
Rajin Kang - VP Communications
rajin.kang@benevolent.ai
Investors:
Fleur Wood
fleur.wood@benevolent.ai
investors@benevolent.ai
